VALEANT PHARMACEUTICALS INTL
VRX
VRX was delisted on the 27th of September, 2010.
2 hedge funds and large institutions have $639K invested in VALEANT PHARMACEUTICALS INTL in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
3% less capital invested
Capital invested by funds: $657K → $639K (-$18K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Colony Group
Boston,
Massachusetts
|
+$626K |
| 2 |
WRM
Westport Resources Management
Westport,
Connecticut
|
+$13K |
Top Sellers
VRX Hedge Fund Activity: Q3 2014 in Review
2 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q3 2014, worth a combined $639K — down 2.7% from $657K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new VRX positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Colony Group, opening a new position worth an estimated $626K.
- 2 institutional investors held VALEANT PHARMACEUTICALS INTL (VRX) as of Q3 2014, up from 1 in Q2 2014.
- Funds reported $639K of VALEANT PHARMACEUTICALS INTL stock for Q3 2014, down 2.7% quarter-over-quarter.
- 2 funds opened new VALEANT PHARMACEUTICALS INTL positions in Q3 2014 and 0 closed out, a net change of +2 holders.
- The largest VALEANT PHARMACEUTICALS INTL buyer in Q3 2014 was Colony Group, an estimated $626K added.
Based on aggregated 13F filings for Q3 2014.